Back to NAI500

Company Profile

Immuron Limited is developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. Immuron has two commercially available products – Travelan® and Protectyn® and four clinical programs: Travelan® (IMC: Phase 2 CHIM trial), Travelan® (USU: Phase 4 field study), CampETEC (NMRC: Phase 2 CHIM trial), IMM-529 (IMC: Protocol development phase, Phase 2 trial). Travelan® sales are growing strongly as overseas travel rebounds. CampETEC Phase 2 clinical trial completed inpatient phase in December 2023. Topline results were released for Travelan® (IMM-124E) Phase 2 CHIM trial in March 2024. Uniformed Services University has recruited ~75% of 866 active military personnel in a Travelan® field clinical trial. Travelan® is an oral passive immunotherapy that prophylactically reduces the likelihood of traveler’s diarrhea commonly caused by pathogenic bacteria and the toxins they produce. Travelan® taken with meals binds to diarrhea-causing bacteria and prevents colonization and the pathogens associated with traveler’s diarrhea.

Corporate Speaker

Steven Lydeamore
CEO

Mr. Lydeamore has >30 years international pharma experience, working in Australia, Canada and USA. Mr. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This includes valuable experience in sales and marketing, manufacturing, and research and development, business development, licensing and acquisitions and, finance.

Mr. Lydeamore was Chief Executive Officer of Anatara Lifesciences Limited (ASX:ANR), during which time the company successfully transitioned from a preclinical to a clinical company following development of a gastrointestinal tract delivery technology from which two products have commenced human clinical trials. At Apotex, Mr. Lydeamore led an international specialty pharma division with >$100 million in sales and >150 employees and also an international generic pharma division with>$550 million in sales and >1550 employees.

Company Website

Stock Info:

NASDAQ:IMRN, ASX:IMC